Table 1 Main clinical characteristics of study patients according to Sativex® response status
All patients (n = 12) | Responders (n = 7) | Non-responders (n = 5) | P-value* | |
|---|---|---|---|---|
age at T0; years, median (range) | 51 (36—73) | 50 (43—54) | 62 (36—73) | p = 0.13 |
male gender; N(%) | 7 (58%) | 6 (86%) | 1 | n.a |
disease duration at T0; years, median (range) | 21.5 (10—37) | 22 (12—37) | 21 (10—33) | p = 0.91 |
EDSS score at T0; median (range) | 6.0 (4.5—8.0) | 6.5 (5.0—8.0) | 5.5 (4.5—7) | p = 0.34 |
spasticity NRS at T0; median (range) | 8 (5—9) | 7 (5—9) | 8 (8- 9) | p = 0.12 |
spasticity NRS at T1; median (range) | 6.5 (4—8) | 5 (4—7) | 7 (7—8) | |
∆NRS T1-T0; %, median (range) | 21% (0—33%) | 25% (20%—33%) | 12.5% (0—12.5%) |